Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Cardiac glycosides do not inhibit the growth of the triple-negative breast cancer cell line MDA-MB231 in vitro.
  • Fig. S2. Establishment of ICb-2555MB, an orthotopic PDX model of group 3 MB.
  • Fig. S3. Assessment of long-surviving ICb-2555MB digoxin-treated mice for tumor formation.
  • Fig. S4. Digoxin plasma trough concentrations in tumor-bearing mice.
  • Fig. S5. Comparison of alternative single-agent digoxin treatment regimen with ionizing radiation alone in a group 3 model of MB.
  • Fig. S6. Comparison of a combination of digoxin and radiation with single-agent digoxin alone in a group 3 model of MB.
  • Fig. S7. Quality assessment of DFNs.
  • Table S1. Summary of patient data used to generate driver networks.
  • Table S6. Comparison of drug prediction performance between the two computational methods (DSNI-DFN versus CMAP-GSEA).
  • Table S9. Digoxin plasma trough concentrations in individual tumor-bearing mice.
  • Table S10. Thirty most differentially expressed genes after digoxin treatment of an orthotopic PDX model (ICb-2555MB) of group 3 MB.
  • Table S11. Thirty most differentially expressed genes after digoxin treatment of an orthotopic PDX model (ICb-1078MB) of group 4 MB.
  • References (4853)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S2 (Microsoft Excel format). Driver genes that consist of somatic mutated genes, copy number variation genes, and differentially expressed genes in group 3 MB.
  • Table S3 (Microsoft Excel format). Driver genes that consist of somatic mutated genes, copy number variation genes, and differentially expressed genes in group 4 MB.
  • Table S4 (Microsoft Excel format). Identified driver signaling networks for group 3 MB.
  • Table S5 (Microsoft Excel format). Identified driver signaling networks for group 4 MB.
  • Table S7 (Microsoft Excel format). Ranking order of drugs in DSNI-DFN for group 3 MB.
  • Table S8 (Microsoft Excel format). Ranking order of drugs in CMAP-GSEA for group 3 MB.
  • Table S12 (Microsoft Excel format). Pathway enrichment analysis results using differentially expressed genes in digoxin-treated orthotopic PDX tumors of group 3 MB.
  • Table S13 (Microsoft Excel format). Pathway enrichment analysis results using differentially expressed genes in digoxin-treated orthotopic PDX tumors of group 4 MB.